Oncology Medical News about cutaneous melanoma;regulation of RUNX3 Tumor Suppressor Gene Expression

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma
Clinical Cancer Research, 05/05/09

Kitago M et al. - In a study to assess expression of RUNX3 in cutaneous melanoma and its regulatory mechanisms relative to tumor progression, it was found that RUNX3 is down-regulated during melanoma progression and miR-532-5p is a regulatory factor of RUNX3 expression.

Methods

Expression of RUNX3 mRNA and miR-532-5p (microRNA) was assessed in melanoma lines and in primary and metastatic melanoma tumors.
RUNX3 promoter region hypermethylation was assessed as a possible regulator of RUNX3 expression using methylation-specific PCR.
To investigate the relation between RUNX3 and miR-532-5p, anti–miR-532-5p was transfected into melanoma lines.

Results

RUNX3 mRNA expression was down-regulated in 11 of 11 (100%) metastatic melanoma lines relative to normal melanocytes.
Among 123 primary and metastatic melanoma tumors and 12 normal skin samples, RUNX3 expression was significantly down-regulated in primary melanomas (n = 82) and in melanoma metastasis (n = 41) vs normal skin (n = 12).
This suggested that RUNX3 down-regulation may play a role in the development and progression of melanoma.
Assessment of RUNX3 promoter region methylation showed that only 5 of 17 (29%) melanoma lines, 2 of 52 (4%) primary melanomas, and 5 of 30 (17%) metastatic melanomas had hypermethylation of the promoter region.
miR-532-5p was identified as a target of RUNX3 mRNA sequences.
miR-532-5p expression was shown to be significantly up-regulated in melanoma lines and metastatic melanoma tumors relative to normal melanocytes and primary melanomas, respectively.
Inhibition of miR-532-5p up-regulated both RUNX3 mRNA and protein expression.

<< Previous
Aspirin and non-steroidal anti-inflammatory drugs for cancer...

Next >>
Mutation-specific antibodies for the detection of EGFR mutations...